Investigational New Drug– tag –
-
Voyager Therapeutics Receives FDA IND Clearance for VY1706, First Tau-Targeted Gene Therapy, to Begin Alzheimer’s Disease Phase 1 Trial
Cell & Gene Therapy Review USA Overview Voyager Therapeutics announced that its Investigational New Drug (IND) application for VY1706, a tau-targeted gene therapy for Alzheimer's disease, has been cleared by the FDA. VY1706 is a potent a... -
CRISPR Gene Editing Utilized: First Leishmaniasis Vaccine Receives FDA IND Approval, Advancing to Phase 1 Clinical Trial
Ohio State News USA Overview The first leishmaniasis vaccine, developed by researchers at Ohio State University, is set to begin a Phase 1 clinical trial after receiving Investigational New Drug (IND) approval from the FDA. This innovati... -
WuXi Biologics Hosts Third CRDMO Day in Tokyo, Accelerating Japanese Biopharma Innovation
PR Newswire Japan Overview WuXi Biologics successfully hosted its third CRDMO Day in Tokyo, gathering key leaders and experts from Japan's biopharmaceutical sector to discuss market trends and best practices in biologics innovation. The ... -
ProBio and Curocell Achieve BLA Approval for Next-Gen CD19-Targeted CAR-T Therapy, Initiating Commercial Production in South Korea
ProBio CDMO South Korea Overview ProBio CDMO and Curocell have secured Biologics License Application (BLA) approval for anbalcabtagene autoleucel (Anbal-cel; CRC01), their next-generation CD19-targeted CAR-T cell therapy for relapsed or ...
